Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L F Massuger

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Anticancer Research|November 1, 1991
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic miceL F Massuger, O C Boerman, F H Corstens, et al.
European Journal of Nuclear Medicine|November 3, 1998
Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administrationW C Buijs, J G Tibben, O C Boerman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1990
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibodyL F Massuger, P Kenemans, R A Claessens, et al.
Nuclear Medicine Communications|July 1, 1991
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancerL F Massuger, R A Claessens, P Kenemans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancerN Hoogerbrugge, P Bult, L M de Widt-Levert, et al.
Journal of the National Cancer Institute|June 16, 1993
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2J G Tibben, O C Boerman, R A Claessens, et al.
International Journal of Cancer|January 21, 1991
Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervixK A Yedema, P Kenemans, T Wobbes, et al.
Gynecologic Oncology|April 20, 2016
Improved outcomes due to changes in organization of care for patients with ovarian cancer in the NetherlandsF A Eggink, C H Mom, R F Kruitwagen, et al.
British Journal of Cancer|April 12, 2007
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyB B J Hermsen, R I Olivier, R H M Verheijen, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2020
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34<sup>+</sup> progenitor-derived NK cellsJ M R Van der Meer, R J A Maas, K Guldevall, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Anticancer Research|November 1, 1991
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic miceL F Massuger, O C Boerman, F H Corstens, et al.
European Journal of Nuclear Medicine|November 3, 1998
Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administrationW C Buijs, J G Tibben, O C Boerman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1990
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibodyL F Massuger, P Kenemans, R A Claessens, et al.
Nuclear Medicine Communications|July 1, 1991
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancerL F Massuger, R A Claessens, P Kenemans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancerN Hoogerbrugge, P Bult, L M de Widt-Levert, et al.
Journal of the National Cancer Institute|June 16, 1993
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2J G Tibben, O C Boerman, R A Claessens, et al.
International Journal of Cancer|January 21, 1991
Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervixK A Yedema, P Kenemans, T Wobbes, et al.
Gynecologic Oncology|April 20, 2016
Improved outcomes due to changes in organization of care for patients with ovarian cancer in the NetherlandsF A Eggink, C H Mom, R F Kruitwagen, et al.
British Journal of Cancer|April 12, 2007
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyB B J Hermsen, R I Olivier, R H M Verheijen, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2020
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34<sup>+</sup> progenitor-derived NK cellsJ M R Van der Meer, R J A Maas, K Guldevall, et al.
Pageof 6